|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells显示文摘AIM: To analyze the relevance of the microRNA miR-196a for colorectal oncogenesis. METHODS: The impact of miR-196a on the restriction targets HoxA7, HoxB8, HoxC8 and HoxD8 was analyzed by reverse transcription polymerase chain reaction (RT-PCR) after transient transfection of SW480 cancer cells. The miR-196a transcription profile in colorectal cancer samples, mucosa samples and diverse cancer cell lines was quantifi ed by RT-PCR. Transiently miR-196a-transfected colorectal cancer cells were used for diverse functional assays in vitro and for a xenograft lung metastasis model in vivo. RESULTS: HoxA7, HoxB8, HoxC8 and HoxD8 were restricted by miR-196a in a dose-dependent and gene-specific manner. High levels of miR-196a activated the AKT signaling pathway as indicated by increased phosphorylation of AKT. In addition, high levels of miR-196a promoted cancer cell detachment,migration, invasion and chemosensitivity towards platin derivatives but did not impact on proliferation or apoptosis. Furthermore, miR-196a increased the development of lung metastases in mice after tail vein injection. CONCLUSION: miR-196a exerts a pro-oncogenic influence in colorectal cancer. | Carl Christoph Schimanski Kirsten Frerichs Fareed Rahman Martin Berger Hauke Lang Peter R Galle Markus Moehler Ines Gockel | 2009 | World Journal of Gastroenterology2009，15，17： | 40 |
| 2 | Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg显示文摘AIM:To investigate the outcome of palliative chemotherapy in old patients with gastroesophageal cancer at the National Center for Tumor Diseases,Heidelberg.METHODS:Using a prospectively generated database,we retrospectively analyzed 55 patients≥70years under palliative chemotherapy for advanced gastroesophageal cancer at the outpatient clinic of the National Center for Tumor Diseases Heidelberg,Germany between January 2006 and December2013.Further requirements for inclusion were(1)histologically proven diagnosis of gastroesophageal cancer;(2)advanced(metastatic or inoperable)disease;and(3)no history of radiation or radiochemotherapy.The clinical information included Eastern Cooperative Oncology Group performance status(ECOG PS),presence and site of metastases at diagnosis,date of previous surgery and perioperative chemotherapy,start and stop date of first-line treatment,toxicities and consecutive dosage reductions of first-line treatment,response to first-line therapy,date of progression,usage of second-line therapies and date and cause of death.Survival times[progression-free survival(PFS),overall survival(OS)and residual survival(RS)]were calculated.Toxicity and safety were examined.Prognostic factors including ECOG PS,age and previousperioperative treatment were analyzed.RESULTS:Median age of our cohort was 76 years.86%of patients received a combination of two cytotoxic drugs.76 percent of patients had an oxaliplatin-based first-line therapy with the oxaliplatin and 5-fluorouracil regimen being the predominantely chosen regimen(69%).Drug modifications due to toxicity were necessary in 56%of patients,and 11%of patients stopped treatment due to toxicities.Survival times of our cohort are in good accordance with the major phaseⅢtrials that included mostly younger patients:PFS and OS were 5.8 and 9.5 mo,respectively.Survival differed significantly between patient groups with low(≤1)and high(≥2)ECOG PS(12.7 mo vs 3.8 mo,P<0.001).Very old patients(≥75 years)did not show a worse outcome in terms of survival.Patients receiving secondline treatment(51%)had a significantly longer RS than patients with best supportive care(6.8 vs 1.4 mo,P=0.001).Initial ECOG PS was a strong prognostic factor for PFS,OS and RS.CONCLUSION:Old patients with non-curable gastroesophageal cancer should be offered chemotherapy,and ECOG PS is a tool for balancing benefit and harm upfront.Second-line treatment is reasonable. | Anne Katrin Berger Stefanie Zschaebitz Christine Komander Dirk Jger Georg Martin Haag | 2015 | World Journal of Gastroenterology2015，21，16： | 6 |
| 3 | Bcl-x_L and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells显示文摘AIM: To explore the role of Bcl-xL and Myeloid cell leukaemia (Mcl)-1 for the apoptosis resistance of colorectal carcinoma (CRC) cells towards current treat-ment modalities. METHODS: Bcl-xL and Mcl-1 mRNA and protein ex-pression were analyzed in CRC cell lines as well as human CRC tissue by Western blot,quantitative PCRand immunohistochemistry. Bcl-xL and Mcl-1 protein expression was knocked down or increased in CRC cell lines by applying specific siRNAs or expression plas-mids,respectively. After modulation of protein expres-sion,CRC cells were treated with chemotherapeutic agents,an antagonistic epidermal growth factor recep-tor (EGFR1) antibody,an EGFR1 tyrosine kinase inhibi-tor,or with the death receptor ligand TRAIL. Apoptosis induction and cell viability were analyzed. RESULTS: Here we show that in human CRC tis-sue and various CRC cell lines both Bcl-xL and Mcl-1 are expressed. Bcl-xL expression was higher in CRC tissue than in surrounding non-malignant tissue,both on protein and mRNA level. Mcl-1 mRNA expression was significantly lower in ma-lignant tissues. However,protein expression was slightly higher. Viability rates of CRC cells were significantly decreased after knock down of Bcl-xL expression,and,to a lower extent,after knock down of Mcl-1 expression. Furthermore,cells with reduced Bcl-xL or Mcl-1 expression was more sensitive towards oxaliplatin-and irinotecan-induced apoptosis,and in the case of Bcl-xL also towards 5-FU-induced apoptosis. On the other hand,upregulation of Bcl-xL by transfec-tion of an expression plasmid decreased chemothera-peutic drug-induced apoptosis. EGF treatment clearly induced Bcl-xL and Mcl-1 expression in CRC cells. Apop-tosis induction upon EGFR1 blockage by cetuximab or PD168393 was increased by inhibiting Mcl-1 and Bcl-xL expression. More strikingly,CD95-and TRAIL-induced apoptosis was increased by Bcl-xL knock down. CONCLUSION: Our data suggest that Bcl-xL and,to a lower extent,Mcl-1,are important anti-apoptotic factors in CRC. Specific downregulation of Bcl-xL is a promising approach to sensitize CRC cells towards chemotherapy and targeted therapy. | Henning Schulze-Bergkamen Roland Ehrenberg Lothar Hickmann Binje Vick Toni Urbanik Christoph C Schimanski Martin R Berger Arno Schad Achim Weber Steffen Heeger Peter R Galle Markus Moehler | 2008 | World Journal of Gastroenterology2008，14，24： | 4 |
| 4 | Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?显示文摘AIM: To define the (co-)expression pattern of target receptor-tyrosine-kinases (RTK) in human gastric adenocarcinoma. METHODS: The (co-)expression pattern of VEGFR1-3,PDGFRα/b and EGFR1 was analyzed by RT-PCR in 51 human gastric adenocarcinomas. In addition,IHC staining was applied for confirmation of expression and analysis of RTK localisation. RESULTS: The majority of samples revealed a VEGFR1 (98%),VEGFR2 (80%),VEGFR3 (67%),PDGFRα (82%) and PDGFRβ(82%) expression,whereas only 62% exhibited an EGFR1 expression. 78% of cancers expressed at least four out of six RTKs. While VEGFR1-3 and PDGFRα revealed a predominantly cytoplasmatic staining in tumor cells,accompanied by an additional nuclear staining for VEGFR3 ,EGFR1 was almost exclusively detected on the membrane of tumor cells. PDGFRβ was restricted to stromal pericytes,which also depicted a PDGFRα expression.receptor-tyrosine-kinases coexpression in gastric adenocarcinoma and might therefore encourage an application of multiple-target RTK-inhibitors within a combination therapy. | Daniel Drescher Markus Moehler Ines Gockel Kirsten Frerichs Annett Müller Friedrich Dünschede Thomas Borschitz Stefan Biesterfeld Martin Holtmann Thomas Wehler Andreas Teufel Kerstin Herzer Thomas Fischer Martin R Berger Theodor Junginger Peter R Galle Carl C Schimanski | 2007 | World Journal of Gastroenterology2007，13，26： | 4 |
| 5 | Sludge thickening in a wastewater treatment plant using a modified hydrocyclone显示文摘The main application of hydrocyclones in most industry sectors is the separation of particles from liquids.For thickening,however,the separation properties of the cyclone should be adjustable,which requires a different operating mode.Therefore,we investigated an add-on thickening module,consisting of a conical plug and a secondary vortex finder in the underflow of the hydrocyclone.Laboratory scale experiments are carried out to investigate the function of the concept of annular gap modification by the use of the thickening module.In the second step,we transferred this concept to industrial scale for field tests at a municipal wastewater treatment plant.In the field tests,geometrical properties(annular gap modification)and operational parameters(volume flow rate,sludge type)were investigated.The results show that thickening in terms of increasing the total solids content of sludge is possible with the modified hydrocyclone.In the field tests,a thickening factor(total solids content of thickened sludge related to feed sludge)of 1.31(average)was reached for digested sludge.Hence,a hydrocyclone could be a promising addition in wastewater treatment plants for dewatering of sludge. | Thomas Senfter Lukas Fritsch Manuel Berger Tobias Kofler Christian Mayerl Martin Pillei Michael Kraxner | 2021 | Carbon Resources Conversion2021，4，1： | 3 |
| 6 | Comparison of Copeptin, B-Type Natriuretic Peptide, and Amino-Terminal Pro-B-Type Natriuretic Peptide in Patients With Chronic Heart Failure显示文摘 | Stephanie Neuhold Martin Huelsmann Guido Strunk Brigitte Stoiser Joachim Struck Nils G. Morgenthaler Andreas Bergmann Deddo Moertl Rudolf Berger Richard Pacher | 2008 | Journal of the American College of Cardiology2008，，4： | 3 |
| 7 | The major genetic determinants of HIV-1control affect HLA class I peptide presentation显示文摘 | International HIV Controllers Study Pereyra F Jia X McLaren P J Telenti A de Bakker P I Walker B D Ripke S Brumme C J Pulit S L Carrington M Kadie C M Carlson J M Heckerman D Graham R R Plenge R M Deeks S G Gianniny L Crawford G Sullivan J Gonzalez E Davies L Camargo A Moore JM Beattie N Gupta S Crenshaw A Burtt N P Guiducci C Gupta N Gao X Qi Y Yuki Y Piechocka-Trocha A Cutrell E Rosenberg R Moss K L Lemay P O'Leary J Schaefer T Verma P Toth I Block B Baker B Rothchild A Lian J Proudfoot J Alvino D M Vine S Addo M M Allen T M Altfeld M Henn M R Le Gall S Streeck H Haas D W Kuritzkes D R Robbins G K Shafer R W Gulick R M Shikuma C M Haubrich R Riddler S Sax P E Daar E S Ribaudo H J Agan B Agarwal S Ahern R L Allen B L Altidor S Altschuler E L Ambardar S Anastos K Anderson B Anderson V Andrady U Antoniskis D Bangsberg D Barbaro D Barrie W Bartczak J Barton S Basden P Basgoz N Bazner S Bellos N C Benson A M Berger J Bernard N F Bernard A M Birch C Bodner S J Bolan R K Boudreaux E T Bradley M Braun J F Brndjar J E Brown S J Brown K Brown S T Burack J Bush LM Cafaro V Campbell O Campbell J Carlson R H Carmichael J K Casey K K Cavacuiti C Celestin G Chambers S T Chez N Chirch L M Cimoch P J Cohen D Cohn LE Conway B Cooper D A Cornelson B Cox D T Cristofano M V Cuchural G Jr Czartoski J L Dahman J M Daly J S Davis B T Davis K Davod S M DeJesus E Dietz C A Dunham E Dunn M E Ellerin T B Eron J J Fangman J J Farel C E Ferlazzo H Fidler S Fleenor-Ford A Frankel R Freedberg K A French N K Fuchs JD Fuller J D Gaberman J Gallant J E Gandhi R T Garcia E Garmon D Gathe J C Jr Gaultier C R Gebre W Gilman F D Gilson I Goepfert P A Gottlieb M S Goulston C Groger R K Gurley T D Haber S Hardwicke R Hardy W D Harrigan P R Hawkins T N Heath S Hecht F M Henry W K Hladek M Hoffman R P Horton J M Hsu R K Huhn G D Hunt P Hupert M J Illeman M L Jaeger H Jellinger R M John M Johnson J A Johnson K L Johnson H Johnson K Joly J Jordan W C Kauffman C A Khanlou H Killian R K Kim A Y Kim D D Kinder C A Kirchner J T Kogelman L Kojic E M Korthuis P T Kurisu W Kwon D S LaMar M Lampiris H Lanzafame M Lederman M M Lee D M Lee J M Lee M J Lee E T Lemoine J Levy J A Llibre J M Liguori M A Little S J Liu A Y Lopez A J Loutfy M R Loy D Mohammed D Y Man A Mansour M K Marconi V C Markowitz M Marques R Martin J N Martin H L Jr Mayer K H McElrath M J McGhee T A McGovern B H McGowan K McIntyre D Mcleod GX Menezes P Mesa G Metroka CE Meyer-Olson D Miller A O Montgomery K Mounzer K C Nagami E H Nagin I Nahass R G Nelson M O Nielsen C Norene D L O'Connor D H Ojikutu B O Okulicz J Oladehin O O Oldfield E C Olender S A Ostrowski M Owen WF Jr Pae E Parsonnet J Pavlatos A M Perlmutter A M Pierce M N Pincus J M Pisani L Price L J Proia L Prokesch R C Pujet H C Ramgopal M Rathod A Rausch M Ravishankar J Rhame F S Richards C S Richman D D Rodes B Rodriguez M Rose R C 3rd Rosenberg E S Rosenthal D Ross P E Rubin D S Rumbaugh E Saenz L Salvaggio M R Sanchez WC Sanjana V M Santiago S Schmidt W Schuitemaker H Sestak P M Shalit P Shay W Shirvani V N Silebi V I Sizemore J M Jr Skolnik P R Sokol-Anderson M Sosman J M Stabile P Stapleton J T Starrett S Stein F Stellbrink H J Sterman FL Stone V E Stone D R Tambussi G Taplitz R A Tedaldi E M Telenti A Theisen W Torres R Tosiello L Tremblay C Tribble M A Trinh P D Tsao A Ueda P Vaccaro A Valadas E Vanig T J Vecino I Vega V M Veikley W Wade B H Walworth C Wanidworanun C Ward D J Warner D A Weber R D Webster D Weis S Wheeler D A White D J Wilkins E Winston A Wlodaver C G van't Wout A Wright D P Yang O O Yurdin D L Zabukovic B W Zachary K C Zeeman B Zhao M | 2010 | Science2010，330，6010： | 1 |
| 8 | The practice of evaluation in innovation policy in Europe显示文摘 | Jakob Edler Martin Berger Michael Dinges and Abdullah Gok | 2012 | Re-search Evaluation2012，21，3： | 1 |
| 9 | Do Firms Require an Efficient Innovation System to Develop Innovative Technological Capabilities? Empirical Evidence from Singapore, Malaysia and Thailand 显示文摘 | Berger Martin Diez Javier Revilla | 2006 | International Journal of Technology Management2006，36，13： | 1 |
| 10 | SIBLINGs and SPARC families: Their emerging roles in pancreatic cancer显示文摘Pancreatic cancer has a considerably poor prognosis with a 5-year survival probability of less than 5%when all stages are combined.Pancreatic cancer is characterized by its dense stroma,which is involved in the critical interplay with the tumor cells throughout tumor progression and furthermore,creates a barrier restricting efficient penetration of therapeutics.Alterations in a large number of genes are reflected by a limited number of signaling pathways,which are potential targets.Understanding more about the molecular basis of this devastating cancer type regarding tumor microenvironment,distinct subpopulations of cells,epithelial-to-mesenchymal transition and inflammation will lead to the development of various targeted therapies for controlling tumor growth and metastasis.In this complex scenario of pancreatic cancer,especially members of the'small integrin binding ligand N-linked glycoproteins'(SIBLINGs)and'secreted protein acidic and rich in cysteine'(SPARC)families have emerged due to their prominent roles in properties including proliferation,dif-ferentiation,apoptosis,adhesion,migration,angiogenesis,wound repair and regulation of extracellular matrix remodeling.SIBLINGs consist of five members,which include osteopontin(OPN),bone sialoprotein,dentin matrix protein 1,dentin sialophosphoprotein and matrix extracellular phosphoglycoprotein.The SPARC family of modular extracellular proteins is comprised of SPARC/osteonectin(ON)and SPARC-like 1(hevin);secreted modular calcium binding proteins;testicans and follistatin-like protein.In this review,we especially focus on OPN and ON,elaborating on their special and growing importance in pancreatic cancer diagnosis and prognosis. | Ferda Kaleagasioglu Martin R Berger | 2014 | World Journal of Gastroenterology2014，20，40： | 1 |
| 11 | The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and predisposes to cirrhosis in HCV genotype 1-infected Caucasian patients显示文摘 | Hans Dieter Nischalke Cordula Berger Carolin Luda Tobias Müller Thomas Berg Martin Coenen Benjamin Kr?mer Christian K?rner Jonel Trebicka Frank Grünhage Frank Lammert Jacob Nattermann Tilman Sauerbruch Ulrich Spengler | 2011 | Journal of Hepatology2011，，4： | 1 |
| 12 | Riproximin: A type II ribosome inactivating protein with anti-neoplasticpotential induces IL24/MDA-7 and GADD genes in colorectal cancer cell lines显示文摘 | Asim Pervaiz Hassan Adwan Martin Berger | 2015 | International Journal of Oncology2015，，3： | 1 |
| 13 | The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats显示文摘 | Rasmussen K Martin H Berger JE | | 0，，02： | 1 |
| 14 | Lifelong exposure to di-(2-ethylhexyl)-phthalate induces tumors in liver and testes of Sprague–Dawley rats显示文摘 | Cristina Voss Heide Zerban Peter Bannasch Martin R. Berger | 2004 | Toxicology2004，，3： | 1 |
| 15 | Analytical challenges hamper perfluoroalkyl research 显示文摘 | Martin J W Kannan K Berger U etal | 2004 | Environmental Science & Technology2004，538，13： | 1 |
| 16 | Aroma Compound Production in Cheese Curd by Coculturing with Selected Yeast and Bacteria显示文摘 | N Martin C Berger C Le Du | 2001 | J Dairy Sci2001，84，： | 1 |
| 17 | Dickkopf-3 maintains the PANC-1 human pancreatic tumor cells in a dedifferentiatedstate显示文摘 | Christoph Zenzmaier Martin Hermann Paul Hengster Peter Berger | 2012 | International Journal of Oncology2012，，1： | 1 |
| 18 | Paediatric anaesthesia and in-halation agents 显示文摘 | MARTIN J BERGER T M | 2005 | Best Practice & Research ClinicalAnaesthesiology2005，19，3： | 1 |
| 19 | Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer显示文摘 | Gerwin Heller Joseph Geradts Barbara Ziegler Irene Newsham Martin Filipits Eva-Maria Markis-Ritzinger Daniela Kandioler Walter Berger Wolfgang Stiglbauer Dieter Depisch Robert Pirker Christoph C. Zielinski Sabine Z?chbauer-Müller | 2007 | Breast Cancer Research and Treatment2007，，： | 1 |
| 20 | Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231GFP breast cancer cells in?vitro and on osteolytic lesions induced in?vivo by this cell line in nude rats显示文摘 | Jenny Peterschmitt Tobias B?uerle Martin R. Berger | 2007 | Clinical & Experimental Metastasis2007，，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员